SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.

Trial Details

NCT ID
NCT05900882
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Selinexor
  • Bortezomib
  • Lenalidomide
  • Dexamethasone
Locations (sample)
  • Changzhou, Jiangsu, China|31.77359,119.95401
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nantong, Jiangsu, China|32.03028,120.87472
  • Taizhou, Jiangsu, China|32.49069,119.90812

Key Eligibility Criteria

  • Men and women aged with18-75 years old.
  • Confirmed diagnosis of Multiple Myeloma(MM) (IMWG consensus guidelines)
  • Newly diagnosed patients presenting with extramedullary disease (EMD) including solely paraskeletal plasmacytoma, plasmacytoma of soft tissue and o…
  • ANC≥1.0\*10\^9/L, HGB≥75\*10\^9/L, PLT≥50\*10\^9/L (≥50% of bone marrow nucleated cells are plasma cells).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →